Access to the population, financing and availability times of antineoplastic drugs incorporated into the SUS between 2012 and 2024

Resumo

Objective: The study aimed to evaluate the effectiveness of the process of incorporating
antineoplastic drugs into the Sistema Único de Saúde (SUS) from 2012 to October
2024. Whether these treatments are being made available in a timely manner and what
limitations exist was investigated. Methods: A retrospective analysis of CONITEC reports
was used, where data on 24 drugs was collected, including dates of incorporation and
publication in the Diário Oficial da União, as well as information on published oncology
therapeutic guidelines, antineoplasic drug costs and transfer values for Autorizações de
Procedimentos Ambulatoriais (APAC). Results: The results showed that, from a total of
24 antineoplasic drugs incorporated during the analyzed period, a significant amount
experience limitations on access, including 7 drugs not included on therapeutic guide
lines and 15 with insufficient federal transfer values. In total, treatment costs for 15
technologies are over 100% above values determined for APAC. Conclusions: The study
revealed that important barriers compromise availability of incorporated antineoplasic
drugs in SUS, with treatment costs currently significantly outweighting APAC values.
There exists a visible need for efficient alternatives for finance and management in onco
logy, as demonstrated by the examples of blinatumomab and drugs centrally acquired by
the Ministry of Health, to improve access to oncology in the SUS.